Body Composition

Tesamorelin + Ipamorelin

Tesamorelin + Ipamorelin Blend

Visceral-fat-focused GHRH analog paired with a selective GHRP

Research Status: Research compound; Tesamorelin component is FDA-approved Tesa / IPA Blend Tesamorelin/Ipamorelin
Mechanism of Action

How it works

This blend combines Tesamorelin - a GHRH analog with clinical data for reducing visceral adipose tissue - with Ipamorelin, a selective GH secretagogue. The pairing targets GH release through two mechanisms with a body-composition emphasis.

Areas of Research

What the research explores

In published research, Tesamorelin + Ipamorelin has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Tesamorelin's visceral-fat research focus
  • Ipamorelin adds a selective second GH stimulus
  • Studied for body composition
  • Two complementary mechanisms
  • Maintains pulsatile GH physiology
Research Highlight

Tesamorelin is the only GHRH analog FDA-approved specifically to reduce visceral fat (in HIV-associated lipodystrophy), making it the anchor of this body-composition blend.

Safety Profile

Adverse events & gaps

Tesamorelin is well-characterized clinically; Ipamorelin is noted for selectivity. Injection-site reactions and fluid retention reported.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.